Leukine Market Report 2026

Leukine Market Overview

• The Leukine market growth in the historic period has been driven by increasing chemotherapy usage, advancements in cytokine therapy development • Market expansion is supported by increasing demand for post-chemotherapy immune support, expansion of personalized oncology care • Growth Driver: Impact Of Rising Leukemia Incidence On The Leukine Market Growth • Market Trend: Expanding Routes Of Administration And Therapeutic Applications Of Leukine • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Leukine Market?

Leukine (sargramostim) is a medication used to stimulate the production of white blood cells, particularly after chemotherapy or bone marrow transplants. It works by promoting the growth of granulocytes and macrophages to help prevent infections in patients with weakened immune systems. The main formulations in the leukine market are injectable formulation (lyophilized powder) and ready-to-use solutions. Leukine's injectable formulation refers to a lyophilized powder for solution that contains sargramostim, a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). The various routes of administration include subcutaneous injection and intravenous infusion, and several indications including treatment of acute myeloid leukemia (AML), treatment of bone marrow suppression, treatment of neutropenia, and supportive care in cancer patients. The patient demographics include adult patients, pediatric patients, and geriatric patients, and different end users encompass hospitals, oncology clinics, hematology clinics, and research institutions.

What Is The Leukine Market Growth Forecast?

The growth in the forecast period can be attributed to increasing demand for post-chemotherapy immune support, expansion of personalized oncology care, growing investments in immunostimulatory therapies, rising focus on reducing treatment-related complications, increased adoption of biologic supportive therapies. Major trends in the forecast period include increasing use of hematopoietic growth factors in oncology care, rising demand for immune recovery support therapies, growing focus on infection prevention in immunocompromised patients, expansion of supportive cancer care solutions, enhanced optimization of injectable biologic formulations.

What Is The Driver Of The Leukine Market?

The increasing incidence of leukemia is expected to propel the growth of the leukine market going forward. Leukemia is a type of cancer that affects the blood and bone marrow, leading to the abnormal production of white blood cells. The increasing incidence of leukemia may be attributed to factors such as environmental exposures, genetic mutations, lifestyle changes, and improved detection methods. Leukine supports leukemia patients by stimulating the production and activation of white blood cells, particularly neutrophils, to enhance their immune response and accelerate recovery following chemotherapy or bone marrow transplantation, thereby reducing the risk of infection and improving overall treatment outcomes. For instance, in 2024, according to the American Cancer Society, a US-based non-profit cancer advocacy organization, the number of leukemia cases increased to 62,770, reflecting an increase from 59,610 recorded in 2023. Therefore, increasing incidence of leukemia drives the leukine industry.

Key Players In The Global Leukine Market

Major companies operating in the leukine market are Partner Therapeutics Inc.

Global Leukine Market Trends and Insights

The key trend in the leukine market include expanding routes of administration to enhance patient convenience, improve compliance, and optimize therapeutic outcomes. This expansion aims to improve patient compliance, offering easier administration options while maintaining the therapeutic efficacy of the drug. For instance, in April 2024, Partner Therapeutics Inc., a US-based biotech company, announced that its partner, Nobelpharma, a Japan-based pharmaceutical company, received approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for the inhaled use of Leukine (branded as Sargmalin in Japan) to treat autoimmune pulmonary alveolar proteinosis (aPAP). This marks the first regulatory approval for an inhaled recombinant GM-CSF product for this indication. This development highlights the expanding therapeutic applications of Leukine beyond its traditional uses in oncology and radiation exposure scenarios.

What Are Latest Mergers And Acquisitions In The Leukine Market?

In January 2025, Partner Therapeutics, a US-based provider of late-stage biopharmaceutical therapies, partnered with BARDA, a United States–based government health‑security agency, for a Phase 2 study of Leukine (sargramostim, rhu GM‑CSF). With this partnership, the strategic objective is to evaluate safety, select optimal dosing, and use biomarkers to identify sepsis patients who may benefit from immune-modulatory therapy, thereby expanding Leukine’s clinical indications. BARDA is a US–based agency focused on advanced research and development of medical countermeasures for public health emergencies.

What Defines the Leukine Market?

The leukine market consists of sales of leukine injections, and pre-filled syringes. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Leukine Market Report 2026?

The leukine market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the leukine industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.